How Will The Fabry Disease Treatment Market Reach $3.13 Billion By 2029 Amid Global Shifts?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What CAGR And Valuation Are Anticipated For The Fabry Disease Treatment Market?
The market for treating Fabry disease has been expanding robustly in the past few years. The market is predicted to increase from $2.09 billion in 2024 to $2.27 billion in 2025, showing a compound annual growth rate (CAGR) of 8.8%. Factors like heightened awareness and diagnosis rate, wider acceptance of enzyme replacement therapies, more use of chaperone therapies, growth in healthcare infrastructure, an increase in investment for rare disease research, growing population, and enhanced regulatory incentives for orphan drugs have contributed to the market’s growth during the historic period.
In the coming years, the Fabry disease treatment market is anticipated to experience robust growth. The market is set to expand to $3.13 billion by 2029, with a compound annual growth rate (CAGR) of 8.3%. The growth during this forecasted period can be credited to factors such as the increasing occurrence of the disease, heightened awareness and diagnosis rates, enhancement of healthcare infrastructure, increased investments in rare disease research, growing patient acknowledgment, and widening reimbursement policies. The forecast period will also witness major trends including improvements in gene therapy, developments in enzyme replacement therapies, progress in diagnostic methods, enhancements in innovative therapies, and the incorporation of digital health technologies in patient management.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16421&type=smp
What Market Forces Are Contributing To The Growth Of The Fabry Disease Treatment Market?
The escalating incidence of kidney diseases is predicted to catalyze the expansion of the market for fabry disease treatment. Kidney diseases denote any condition that compromises the kidneys’ functions. A rise in renal disease cases can be attributed to genetic factors, lifestyle choices, environmental influencers, and pre-existing health issues. Fabry disease results from the buildup of globotriaosylceramide (Gb3) in the kidney cells, causing damage and malfunction, emphasizing the essential need for early diagnosis and treatment to prevent kidney-related problems. For example, in December 2023, the Australian Bureau of Statistics, a governmental agency in Australia, disclosed that in 2022, 246,200 individuals (1.0% of the population) were afflicted with kidney disease, indicating a growth of 0.2% from the last decade. As such, the rising incidence of renal diseases is fueling the growth of the fabry disease treatment market.
Which Segmentation Factors Are Critical In The Fabry Disease Treatment Market Analysis?
The fabry disease treatmentmarket covered in this report is segmented –
1) By Treatment: Substrate Reduction Therapy; Enzyme Replacement Therapy; Chaperone Treatment; Other Treatments
2) By Route Of Administration: Oral Route; Intravenous Route
3) By Disease Severity: Classic Fabry Disease; Late-Onset Fabry Disease
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Substrate Reduction Therapy: Migalastat Hydrochloride (Galafold); Other Substrate Reduction Therapies
2) By Enzyme Replacement Therapy: Agalsidase Beta (Fabrazyme); Agalsidase Alfa (Replagal); Other Enzyme Replacement Therapies
3) By Chaperone Treatment: Migalastat Hydrochloride (Galafold)
4) By Other Treatments: Gene Therapy; Symptomatic Treatment
What Are The Dominant Trends Currently Seen In The Fabry Disease Treatment Market?
Key players in the Fabry disease treatment industry are advancing plant cell-powered therapies to increase treatment effectiveness, decrease treatment expenses, and enhance patient results via innovative and sustainable strategies. This approach involves utilizing plant cells to create enzymes that are deficient in those suffering from Fabry disease. These plant-generated enzymes serve as a therapeutic alternative to supplement missing or defective enzymes in the body, with the goal of relieving symptoms and enhancing the wellness of those impacted by Fabry disease. For example, in May 2023, Chiesi Global Rare Diseases, a pharmaceutical company based in Italy, alongside Protalix BioTherapeutics Inc., a pharmaceutical company based in Israel, got approval for ELFABRIO. This enzyme replacement treatment (ERT) creates the recombinant human a-Galactosidase-A enzyme in a plant-cell culture and adapts it with PEGylation to significantly lengthen its half-life. ELFABRIO serves as an alternative treatment option for those living with Fabry disease, reducing episode frequency, enhancing convenience, and overall improving the management of Fabry disease symptoms, which in turn improves patients’ quality of life.
Which Organizations Are At The Forefront Of The Fabry Disease Treatment Market?
Major companies operating in the fabry disease treatment market are Sanofi S.A., GSK plc, Takeda Pharmaceutical Company Limited, CHIESI Farmaceutici S.p.A., Ultragenyx Pharmaceutical Inc., Amicus Therapeutics Inc., JCR Pharmaceuticals Co. Ltd., Sangamo Therapeutics Inc., Idorsia Pharmaceuticals Ltd., Centogene N.V., Protalix BioTherapeutics, Avrobio Inc., ISU Abxis, Synageva BioPharma Corp., Greenovation Biotech GmbH, CANbridge Pharmaceuticals, Freeline, 4D Molecular Therapeutics, Abeona Therapeutics Inc., GC Biopharma Corporation
Access The Complete Report Here:
https://www.thebusinessresearchcompany.com/report/fabry-disease-treatment-global-market-report
Which Region Is Leading Innovation In The Fabry Disease Treatment Market?
North America was the largest region in the fabry disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fabry disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=16421&type=smp
Browse Through More Reports Similar to the Global Fabry Disease Treatment Market 2025, By The Business Research Company
Sewage Treatment Facilities Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/sewage-treatment-facilities-global-market-report
Benign Prostatic Hyperplasia Bph Treatment Devices And Equipment Global Market Report 2025
Wastewater Treatment Equipment Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
